ConvaTec - Analyst consensus and Thursday technicals

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 18:19 CET. Details in the imprint.

ConvaTec (GB00BD3VFW73) is a mid-cap medtech group listed in London. With no fresh corporate announcements on Thursday, the focus shifts to how analysts value the stock and how the chart looks after recent trading sessions.

What analysts currently expect

For ConvaTec, the available data points to a largely positive analyst stance with a predominance of Buy and Hold recommendations, while Sell ratings are rare according to consensus overviews.

MarketScreener data for ConvaTec shows an average analyst target price of about $4.01 per share, compared with a last close near $2.75, implying upside potential from current levels.

How the Thursday chart looks

On the London Stock Exchange, ConvaTec shares have recently been trading in a relatively narrow band, reflecting a calm phase after earlier gains and losses, with no major technical breakouts reported on Thursday.

Based on public quote pages, the stock is trading not far from its 52-week mid-range, which suggests a balanced risk-reward profile rather than a clearly stretched valuation on simple chart metrics.

How the company makes money

ConvaTec generates most of its revenue from medical products for chronic conditions, including advanced wound care, ostomy care, continence and critical care, and infusion care therapies, marketed globally to hospitals, homecare providers and directly to patients.

Where the stock trades today

ConvaTec shares (GB00BD3VFW73) trade on the London Stock Exchange at GBP 2.15 as of 06/18/2026, 17:30 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.